1948 Riken reorganized into Kagaku-Kenkyusho
Launched Penicillin Kaken
1950 Launched Streptomycin Kaken
1952 Kagaku-Kenkyusho renamed Kaken Chemicals
1953 Launched Athletan (anti-trichophyton product)
1962 Kaken Chemicals listed on the First Section of the Tokyo Stock Exchange
1963 Completed Shizuoka Factory
1965 Received the 11th Okochi Memorial Prize
1971 Received the 17th Okochi Memorial Prize
1982 Kaken Chemicals merged with Kakenyaku-Kako to form KAKEN PHARMACEUTICAL CO., LTD.
1987 Launched Artz (anti-osteoarthritis agent)
1988 Kaken Pharma Co., Ltd. established
Launched Adofeed
1989 Launched Ebrantil (anti-dysuria agent)
1992 Launched Procylin
Launched Mentax
1993 Launched Artz Dispo (anti-osteoarthritis agent)
1994 Received the 40th Okochi Memorial Prize
1995 Received the 41st Okochi Memorial Prize
1996 Mentax approved by U.S. Food and Drug Administration
1998 Completed Bunkyo Green Court
Launched Seprafilm (post-operative adhesion barrier)
2000 Won the fiscal 2000 3Rs (Reduce, Reuse and Recycle) Promotion Merit Award and the Minister of Health and Welfare Award
2001 ISO14001 obtained in Shizuoka site
Launched Fiblast Spray (wound-healing agent)
2004 Launched Mentax Spray
2005 Obtained the rights to develop, manufacture and sell bFGF globally
2006 Out-licensed antifungal compound “KP-103” in North America and Europe
2007 Launched Berasus
2011 Launched Lipidil
2014 Launched Clenafin (onychomycosis treatment)
2015 In-licensed BBI-4000 in Japan and certain other Asian countries
2016 Acquired exclusive rights to develop and distribute NexoBrid in Japan
Out-licensed Clenafin/Jublia in South Korea
Launched Regroth dental kit (periodontal regenerative agent)
2017 Launched collaborative research with Numab Therapeutics AG to develop a new antibody drug
Out-licensed Clenafin in Taiwan
2018 Launched Hernicore (lumbar disc herniation treatment)
Out-licensed Clenafin in Hong Kong and Macau
2019 Acquired exclusive rights to distribute Lenabasum (systemic sclerosis and dermatomyositis treatment) in Japan
Out-licensed Clenafin in China
Acquired exclusive rights to develop and distribute Ivermectin lotion 0.5% (head lice treatment) in Japan
2020 Launched Ecclock Gel 5% (primary axillary hyperhidrosis treatment)
2021 Out-licensed Clenafin in Europe
Acquired ARTham Therapeutics Inc. and made it a subsidiary
2023 Acquired exclusive rights to develop and distribute Seladelpar (Primary biliary cholangitis treatment) in Japan
Acquired exclusive rights to develop and distribute Tildacerfont (Congenital adrenal hyperplasia treatment) in Japan